The SMART Hospital & Healthcare of the Future APAC 2016 conference in Singapore from 25th till the 29th of April.

This conference functions was a meeting place and platform for international and Asian leaders and innovators in healthcare to convene and discuss forward looking strategies that will drive transformation in healthcare delivery.

Mr. H. Akerboom, Deputy Ambassador at the Embassy of the Kingdom of the Netherlands, opens the Holland Health Seminar on Friday morning in the Maxwell Chambers. Together with Mark Kramer, a professor at the VU University Medical Center Amsterdam (VUmc), Evert Jan Hoijtink gave a presentation about Patient Centered Integrated Care Treatment and Prevention Programs.

Program Holland Health Seminar

Solution

Portavita Integrated Care System (ICS), our web-based solution for prevention, treatment and healthcare management in a coordinated way. The patients and all involved practitioners use the underlying Electronic Health Record.

We provide a co-operation platform to support primary processes, patient self-management and healthcare organisations with their reporting, research and financial-data needs. Our solution has an integrated messaging system, an authorisation and workflow engine and e-Learning modules.

Input of leading medical professionals and their patients is the basis for the current modules of the system: Anticoagulation, Asthma/COPD, Cardiovascular Risk Management, Diabetes and Elderly Care

Vision

Health of people requires good cooperation between patients and their involved practitioners, irrespective of time and place.

Evidence

Portavita solutions support thousands of medical organisations since 2002. Currently our Dutch, German, Russian and South American customers support over 500.000 patients. They work in a multi-organisational and multi-disciplinary setting. Within these healthcare organisations, 10.000 medical professionals and over 100.000 participating self-management patients use our online solution on a daily basis. These organisations achieve over 80% of patients, treated with Oral AC, to be in their therapeutic range (TTR). In most countries worldwide this is on average 10% lower*. Many countries are performing even seriously lower at higher cost per monitored patient. *German study of Dr. Koerte, a German study of dr. Hortkotte and a large retrospective study of Dr. Boulanger in the United States. 

Partner

Our partner in Singapore is T-Systems Singapore.

Research & Innovation

Portavita supports an eco system of building medical protocol supportive software, gathering results of the medical treatments and sharing this medical data for Research and Analytics. The improvements and refinements are again input for the medical protocols.

An overview:

  • COMMODITY12

A European Union (EU) innovation project in which continuous monitoring devices are connected to the Portavita ICS for diabetes. (www.commodity12.eu)

  • AXLE

In this EU project the focus point is analytics on big medical data with special attention to data protection, patient privacy and scalability (www.axleproject.eu)

  • thrombEVAL

A project to research the applicability of the Dutch based anticoagulation solution for Germany. Munzel T, Wild PS. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL. European Journal of Preventive Cardiology, 2014.

  • Near Patient Testing by care takers in elderly homes

Study into the effectiveness, safety and well-considered introduction of Near-Patient Testing in elderly and nursing homes in The Netherlands. Verstappen WHJM, Land RP van ‘t.Near-Patient Testing (NPT) of coagulation time in health care institutions.

  • Reasons and Barriers for Using a Patient Portal

Study shows the reasons and barriers of patients with diabetes for using a Web portal with access to their own personal health record. Ronda MCM, Dijkhorst-Oei L, Rutten GEHM. Reasons and Barriers for Using a Patient Portal: Survey Among Patients With Diabetes Mellitus. Journal of Medical Internet Research, 2014.

 

Quality and privacy

  • Portavita is ISO 13485:2003 certified since 22 January 2014.
  • Portavita is compliant with the European medical device directive 93/42/EEC (CE label)
  • Portavita complies with the Dutch and German Personal Data Protection Acts.
  • For the Russian market we have a Roszdravnazor registration certificate.

 

Business Model

Together with our local partner we organise a total solution, including medical care providers responsible for the treatment, devices, medication, reimbursement, Standard Operation Procedures, education and ICT. Portavita offers its platform on a “pay per use” basis. One-time investments are related to translation, local hosting, training and potential adaption to the local protocols.

 

Contact

 

Portavita

Evert Jan Hoijtink Founder & CEO
Oostenburgervoorstraat 83a
1018MP Amsterdam
The Netherlands
+31 652 523 541 [mobile]
e.j.hoijtink@portavita.eu
www.portavita.com

T-Systems Singapore Pte Ltd

Deutsche Telekom Centre
23 Tai Seng Drive
Singapore 535224
Singapore
+65 6510 6000 [tel]
contacts@t-systems.com
www.t-systems.com.sg

Project Manager | Singapore & Malaysia
Netherlands Network for Innovation, Technology & Science
Marijke Ten Haaf
marijke-ten.haaf@minbuza.nl
singapore.nlambassade.org